Ryan Downey, Director of Customer Operations, outlines August Bioservices’ capabilities for its customers and what it means to work with them.
They focus on sterile injectables in multiple container sizes from vials to syringes to flexible IV bags— coupled with an analytical services department.
The current CDMO market is constrained for those who need the capacity to start their innovative work, which is where August Bioservices comes in.
With robust tools and a strong team, they can solve difficult challenges with formulation, commercial configuration, the timing of a project, and analytical characterizations.
Proposal for the Public Procurement Act, adoption of a new pharmaceutical legislation, and revision of pharmacovigilance practices should improve patient access to safe and innovative medicines in Europe.
This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.